Latest Threshold Pharmaceuticals (THLD) Headlines
Post# of 95
Posted On: 03/13/2014 2:46:51 PM
Latest Threshold Pharmaceuticals (THLD) Headlines
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial and Operational Results
Marketwire - Thu Mar 06, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2013 and reported on clinical development objectives for TH-302, the Company's investigational hypoxia-targeted drug, which is currently being evaluated in two pivotal Phase 3 clinical trials, one in patients with advanced soft tissue sarcoma and the other in patients with advanced pancreatic cancer. Revenue for the fourth quarter and year ended December 31, 2013 was $3.2 million and $12.5 million, respectively. Net loss for the fourth quarter ended December 31, 2013 was $7.6 million, which included the operating loss of $7.8 million and non-cash income of $0.2 million related to changes in the fair value of the Company's outstanding and exercised warrants that was classified as other income (expense). Net loss for the year ended December 31, 2013 was $28.4 million, which included the operating loss of $26.0 million and non-cash expense of $2.3 million related to changes in the fair value of the Company's outstanding and exercised warrants. As of December 31, 2013, Threshold had $82.0 million in cash, cash equivalents and marketable securities, with no debt outstanding. Subsequent to December 31, 2013, Threshold received a $12.5 million milestone payment, which was earned during the fourth quarter of 2013, under its global license and co-development agreement with Merck KGaA, Darmstadt, Germany. The agreement includes an option for Threshold to co-commercialize TH-302 in the U.S.
5 States Where Pancreatic Cancer Prevalence Is the Highest
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 01, 11:15AM CST
There is no making light of the fact that cancer is a terrible disease, claiming more lives in the U.S. each year save for heart disease. What's even scarier is that cancer prevalence is rising in the U.S., whereas a number of other leading causes of...
3 Biotech Companies That Could Be the Next Intercept or InterMune
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 2:43PM CST
Nearly every industry has witnessed a huge rebound since the market bottomed out in March 2009, but few have delivered as strong a gain since 2012 as the biotech sector. Simply put, biotech stocks are on fire. Venture capital is pouring into the...
Directory of South & Central American Libraries 2013
M2 - Wed Feb 26, 2:23AM CST
This new edition of the Directory of South & Central American Libraries provide essential details on all libraries throughout South and Central America including universities, public and special libraries and including the libraries of institutes and research centres.
Threshold Pharmaceuticals Announces Presentations and Webcasts at Three Upcoming Investor Conferences
Marketwire - Thu Feb 20, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at three upcoming investor conferences:
Stock to Watch: Threshold Pharmaceuticals Down 6.4% (THLD)
Comtex SmarTrend(R) - Mon Feb 03, 12:46PM CST
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's worst performing low-priced stocks, down 6.4% to $4.57 on 1.4x average daily volume. Thus far today, Threshold Pharmaceuticals has traded 828,000 shares, vs. average volume of 587,000 shares per day. The stock has underperformed the Dow (-6.4% to the Dow's -1.7%) and underperformed the S&P 500 (-6.4% to the S&P's -2.0%) during today's trading.
Threshold Pharmaceuticals in Focus: Stock Tumbles 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:59AM CST
Threshold Pharmaceuticals saw a big move last session, as the company’s shares fell nearly 9% on the day
Hot Stock: Threshold Pharmaceuticals, Shares Drop 9.6% (THLD)
Comtex SmarTrend(R) - Mon Jan 27, 11:43AM CST
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's worst performing low-priced stocks, down 9.6% to $4.88 on 1.1x average daily volume. Thus far today, Threshold Pharmaceuticals has traded 604,000 shares, vs. average volume of 555,000 shares per day. The stock has underperformed the Dow (-9.6% to the Dow's -0.4%) and underperformed the S&P 500 (-9.6% to the S&P's -0.8%) during today's trading.
12.6% Return Seen to Date on SmarTrend Threshold Pharmaceuticals Call (THLD)
Comtex SmarTrend(R) - Thu Jan 23, 10:00AM CST
SmarTrend identified an Uptrend for Threshold Pharmaceuticals (NASDAQ:THLD) on November 27th, 2013 at $4.80. In approximately 2 months, Threshold Pharmaceuticals has returned 12.62% as of today's recent price of $5.40.
2 Biotech Stocks Under $10 to Watch
at The Street - Fri Jan 17, 6:00AM CST
Keep these under-$10 biotech stocks on your radar.
How Researchers Are Waging War on the Most Lethal Type of Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 11, 11:31AM CST
Let's face it: The prospect of fighting cancer is scary regardless of what cancer type you're diagnosed with. However, select cancers are certainly more lethal than others. Last year, when we examined the 12 most-diagnosed cancer types, we noted...
Threshold Pharma Completes Enrolment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 3:45PM CST
Threshold Pharma completed enrolling patients in its phase III study, which is being conducted to evaluate TH-302 for the treatment of advanced soft tissue sarcoma.
Threshold Pharmaceuticals Announces Target Enrollment of 620 Patients Achieved in Pivotal Phase 3 Trial of TH-302 in Advanced Soft Tissue Sarcoma
Marketwire - Mon Dec 30, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the target enrollment of 620 patients with advanced soft tissue sarcoma has been achieved in the company's pivotal Phase 3 trial of TH-302, its investigational hypoxia-targeted drug. The enrollment achievement triggers a milestone payment of $12.5 million USD from Merck KGaA, Darmstadt, Germany. Threshold has a global license and co-development agreement with Merck for TH-302, which includes an option for Threshold to co-commercialize in the U.S.
Threshold Pharmaceuticals Reports TH-302 Data at the 55th Annual Meeting of the American Society of Hematology (ASH)
Marketwire - Sat Dec 07, 9:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced that clinical data from two early-stage trials of TH-302, its investigational hypoxia-targeted drug, will be presented at the 55th Annual Meeting of the American Society of Hematology (ASH), taking place December 7 - 10, 2013, New Orleans, LA.
Verastem (VSTM) in Focus: Stock Rises by 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 06, 7:11AM CST
Verastem (VSTM) was a big mover last session, as the company saw its shares rise by over 7% on the day.
Threshold Pharmaceuticals Announces Presentation and Webcast at the Oppenheimer 24th Annual Healthcare Conference
Marketwire - Tue Dec 03, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Oppenheimer 24th Annual Healthcare Conference on December 10, 2013, at 2:10 p.m. ET.
Threshold Pharmaceuticals Announces New Clinical Data on TH-302 and Avastin(R) (Bevacizumab) in Recurrent Glioblastoma Following Bevacizumab Failure
Marketwire - Fri Nov 22, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced early data from the Phase 1 portion of an investigator-sponsored Phase 1/2 trial of its investigational hypoxia-targeted drug TH-302 in combination with Avastin(R) (bevacizumab) in patients with recurrent glioblastoma following bevacizumab failure (Study 4003). No dose-limiting toxicity has been reported to date at doses of TH-302 up to 670 mg/m2 plus bevacizumab at 10 mg/m2 every two weeks. Preliminary data in 14 patients showed TH-302 in combination with bevacizumab was associated with a median time to progression of 2.8 months. One patient achieved a complete response and two patients achieved partial responses. The data will be presented this evening from 7 p.m. to 9 p.m. at the 4th Quadrennial World Federation of Neuro-Oncology (WFNO) meeting held in conjunction with the 18th annual 2013 Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), San Francisco, CA.
Threshold Pharmaceuticals Announces New Data on the Combination of TH-302 and Avastin(R) (bevacizumab) in Recurrent Glioblastoma to Be Presented at WFNO/SNO
Marketwire - Mon Nov 11, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data from an investigator-sponsored Phase 1/2 trial evaluating the combination of its investigational hypoxia-targeted drug TH-302 and Avastin(R) (bevacizumab) in patients with recurrent glioblastoma following bevacizumab failure (Study 4003) will be presented at the 4th Quadrennial World Federation of Neuro-Oncology (WFNO) meeting held in conjunction with the 18th annual 2013 Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO). The 2013 WFNO/SNO meeting will take place November 21-24, San Francisco, CA.
Threshold Pharmaceuticals Announces TH-302 Data to Be Presented at ASH
Marketwire - Thu Nov 07, 8:01AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that clinical data on its investigational hypoxia-targeted drug, TH-302, will be presented at the 55th Annual Meeting of the American Society of Hematology (ASH), December 7 - 10, 2013, in New Orleans, LA. The presentations will report early data from two ongoing clinical trials, one evaluating TH-302 as single-agent monotherapy in patients with advanced leukemias (Abstract #3920), and another evaluating TH-302 with low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (Abstract #1948).
Threshold Pharmaceuticals Reports Third Quarter 2013 Financial and Operational Results
Marketwire - Mon Nov 04, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the third quarter of 2013. Revenue for the third quarter ended September 30, 2013 was $3.2 million. The operating loss for the third quarter ended September 30, 2013 was $5.2 million. The net income for the third quarter ended September 30, 2013 was $1.2 million, which included the operating loss of $5.2 million and non-cash income of $6.4 million related to the changes in fair value of the Company's outstanding and exercised warrants and was classified as other income (expense). As of September 30, 2013, Threshold had $91.9 million in cash, cash equivalents and marketable securities, with no debt outstanding.
Threshold Pharmaceuticals Reports Fourth Quarter and Year End 2013 Financial and Operational Results
Marketwire - Thu Mar 06, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the fourth quarter and year ended December 31, 2013 and reported on clinical development objectives for TH-302, the Company's investigational hypoxia-targeted drug, which is currently being evaluated in two pivotal Phase 3 clinical trials, one in patients with advanced soft tissue sarcoma and the other in patients with advanced pancreatic cancer. Revenue for the fourth quarter and year ended December 31, 2013 was $3.2 million and $12.5 million, respectively. Net loss for the fourth quarter ended December 31, 2013 was $7.6 million, which included the operating loss of $7.8 million and non-cash income of $0.2 million related to changes in the fair value of the Company's outstanding and exercised warrants that was classified as other income (expense). Net loss for the year ended December 31, 2013 was $28.4 million, which included the operating loss of $26.0 million and non-cash expense of $2.3 million related to changes in the fair value of the Company's outstanding and exercised warrants. As of December 31, 2013, Threshold had $82.0 million in cash, cash equivalents and marketable securities, with no debt outstanding. Subsequent to December 31, 2013, Threshold received a $12.5 million milestone payment, which was earned during the fourth quarter of 2013, under its global license and co-development agreement with Merck KGaA, Darmstadt, Germany. The agreement includes an option for Threshold to co-commercialize TH-302 in the U.S.
5 States Where Pancreatic Cancer Prevalence Is the Highest
Sean Williams, The Motley Fool - Motley Fool - Sat Mar 01, 11:15AM CST
There is no making light of the fact that cancer is a terrible disease, claiming more lives in the U.S. each year save for heart disease. What's even scarier is that cancer prevalence is rising in the U.S., whereas a number of other leading causes of...
3 Biotech Companies That Could Be the Next Intercept or InterMune
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 2:43PM CST
Nearly every industry has witnessed a huge rebound since the market bottomed out in March 2009, but few have delivered as strong a gain since 2012 as the biotech sector. Simply put, biotech stocks are on fire. Venture capital is pouring into the...
Directory of South & Central American Libraries 2013
M2 - Wed Feb 26, 2:23AM CST
This new edition of the Directory of South & Central American Libraries provide essential details on all libraries throughout South and Central America including universities, public and special libraries and including the libraries of institutes and research centres.
Threshold Pharmaceuticals Announces Presentations and Webcasts at Three Upcoming Investor Conferences
Marketwire - Thu Feb 20, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at three upcoming investor conferences:
Stock to Watch: Threshold Pharmaceuticals Down 6.4% (THLD)
Comtex SmarTrend(R) - Mon Feb 03, 12:46PM CST
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's worst performing low-priced stocks, down 6.4% to $4.57 on 1.4x average daily volume. Thus far today, Threshold Pharmaceuticals has traded 828,000 shares, vs. average volume of 587,000 shares per day. The stock has underperformed the Dow (-6.4% to the Dow's -1.7%) and underperformed the S&P 500 (-6.4% to the S&P's -2.0%) during today's trading.
Threshold Pharmaceuticals in Focus: Stock Tumbles 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:59AM CST
Threshold Pharmaceuticals saw a big move last session, as the company’s shares fell nearly 9% on the day
Hot Stock: Threshold Pharmaceuticals, Shares Drop 9.6% (THLD)
Comtex SmarTrend(R) - Mon Jan 27, 11:43AM CST
Threshold Pharmaceuticals (NASDAQ:THLD) is one of today's worst performing low-priced stocks, down 9.6% to $4.88 on 1.1x average daily volume. Thus far today, Threshold Pharmaceuticals has traded 604,000 shares, vs. average volume of 555,000 shares per day. The stock has underperformed the Dow (-9.6% to the Dow's -0.4%) and underperformed the S&P 500 (-9.6% to the S&P's -0.8%) during today's trading.
12.6% Return Seen to Date on SmarTrend Threshold Pharmaceuticals Call (THLD)
Comtex SmarTrend(R) - Thu Jan 23, 10:00AM CST
SmarTrend identified an Uptrend for Threshold Pharmaceuticals (NASDAQ:THLD) on November 27th, 2013 at $4.80. In approximately 2 months, Threshold Pharmaceuticals has returned 12.62% as of today's recent price of $5.40.
2 Biotech Stocks Under $10 to Watch
at The Street - Fri Jan 17, 6:00AM CST
Keep these under-$10 biotech stocks on your radar.
How Researchers Are Waging War on the Most Lethal Type of Cancer
Sean Williams, The Motley Fool - Motley Fool - Sat Jan 11, 11:31AM CST
Let's face it: The prospect of fighting cancer is scary regardless of what cancer type you're diagnosed with. However, select cancers are certainly more lethal than others. Last year, when we examined the 12 most-diagnosed cancer types, we noted...
Threshold Pharma Completes Enrolment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 31, 3:45PM CST
Threshold Pharma completed enrolling patients in its phase III study, which is being conducted to evaluate TH-302 for the treatment of advanced soft tissue sarcoma.
Threshold Pharmaceuticals Announces Target Enrollment of 620 Patients Achieved in Pivotal Phase 3 Trial of TH-302 in Advanced Soft Tissue Sarcoma
Marketwire - Mon Dec 30, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that the target enrollment of 620 patients with advanced soft tissue sarcoma has been achieved in the company's pivotal Phase 3 trial of TH-302, its investigational hypoxia-targeted drug. The enrollment achievement triggers a milestone payment of $12.5 million USD from Merck KGaA, Darmstadt, Germany. Threshold has a global license and co-development agreement with Merck for TH-302, which includes an option for Threshold to co-commercialize in the U.S.
Threshold Pharmaceuticals Reports TH-302 Data at the 55th Annual Meeting of the American Society of Hematology (ASH)
Marketwire - Sat Dec 07, 9:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced that clinical data from two early-stage trials of TH-302, its investigational hypoxia-targeted drug, will be presented at the 55th Annual Meeting of the American Society of Hematology (ASH), taking place December 7 - 10, 2013, New Orleans, LA.
Verastem (VSTM) in Focus: Stock Rises by 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 06, 7:11AM CST
Verastem (VSTM) was a big mover last session, as the company saw its shares rise by over 7% on the day.
Threshold Pharmaceuticals Announces Presentation and Webcast at the Oppenheimer 24th Annual Healthcare Conference
Marketwire - Tue Dec 03, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at the Oppenheimer 24th Annual Healthcare Conference on December 10, 2013, at 2:10 p.m. ET.
Threshold Pharmaceuticals Announces New Clinical Data on TH-302 and Avastin(R) (Bevacizumab) in Recurrent Glioblastoma Following Bevacizumab Failure
Marketwire - Fri Nov 22, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today announced early data from the Phase 1 portion of an investigator-sponsored Phase 1/2 trial of its investigational hypoxia-targeted drug TH-302 in combination with Avastin(R) (bevacizumab) in patients with recurrent glioblastoma following bevacizumab failure (Study 4003). No dose-limiting toxicity has been reported to date at doses of TH-302 up to 670 mg/m2 plus bevacizumab at 10 mg/m2 every two weeks. Preliminary data in 14 patients showed TH-302 in combination with bevacizumab was associated with a median time to progression of 2.8 months. One patient achieved a complete response and two patients achieved partial responses. The data will be presented this evening from 7 p.m. to 9 p.m. at the 4th Quadrennial World Federation of Neuro-Oncology (WFNO) meeting held in conjunction with the 18th annual 2013 Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO), San Francisco, CA.
Threshold Pharmaceuticals Announces New Data on the Combination of TH-302 and Avastin(R) (bevacizumab) in Recurrent Glioblastoma to Be Presented at WFNO/SNO
Marketwire - Mon Nov 11, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that new data from an investigator-sponsored Phase 1/2 trial evaluating the combination of its investigational hypoxia-targeted drug TH-302 and Avastin(R) (bevacizumab) in patients with recurrent glioblastoma following bevacizumab failure (Study 4003) will be presented at the 4th Quadrennial World Federation of Neuro-Oncology (WFNO) meeting held in conjunction with the 18th annual 2013 Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO). The 2013 WFNO/SNO meeting will take place November 21-24, San Francisco, CA.
Threshold Pharmaceuticals Announces TH-302 Data to Be Presented at ASH
Marketwire - Thu Nov 07, 8:01AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that clinical data on its investigational hypoxia-targeted drug, TH-302, will be presented at the 55th Annual Meeting of the American Society of Hematology (ASH), December 7 - 10, 2013, in New Orleans, LA. The presentations will report early data from two ongoing clinical trials, one evaluating TH-302 as single-agent monotherapy in patients with advanced leukemias (Abstract #3920), and another evaluating TH-302 with low-dose dexamethasone in patients with relapsed/refractory multiple myeloma (Abstract #1948).
Threshold Pharmaceuticals Reports Third Quarter 2013 Financial and Operational Results
Marketwire - Mon Nov 04, 6:00AM CST
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), today reported financial results for the third quarter of 2013. Revenue for the third quarter ended September 30, 2013 was $3.2 million. The operating loss for the third quarter ended September 30, 2013 was $5.2 million. The net income for the third quarter ended September 30, 2013 was $1.2 million, which included the operating loss of $5.2 million and non-cash income of $6.4 million related to the changes in fair value of the Company's outstanding and exercised warrants and was classified as other income (expense). As of September 30, 2013, Threshold had $91.9 million in cash, cash equivalents and marketable securities, with no debt outstanding.
(0)
(0)Molecular Templates Inc. (MTEM) Stock Research Links
Scroll down for more posts ▼